The authors speculate that less efficient immune complex handling by low binders may contribute to lupus pathogenesis and that targeting FcγRIIIa/CD16 to improve receptor expression and function may be a potential therapeutic approach. This evidence concerns the gene FCGR3A and systemic lupus erythematosus.